The South Korean company Stand Up Therapeutics Co., Ltd. specialises in gene therapy for paralysis caused by spinal cord injury. To develop a GMP-grade gene delivery system, Stand Up Therapeutics announced that it had contracted with VectorBuilder Inc., a world leader in gene delivery technologies.

In terms of the production of custom viral and non-viral gene delivery vectors, VectorBuilder is unrivalled. It is a global corporation having locations across the globe, including the Americas, Europe, Asia, Oceania, and Israel. The corporation has numerous locations across the globe, including in North America, Europe, China, Japan, Korea, Australia, and Israel in addition to its headquarters in Chicago, Illinois. More than 80,000 unique vectors are created annually for academics around the world. Over 50,000 customers and tens of thousands of institutions, including the world's leading pharmaceutical companies and universities, purchase gene therapy products and delivery systems from VectorBuilder every year because of the company's Good Manufacturing Practice (GMP) facilities for these products. We provide services and products to transport gene therapy.

According to the terms of the agreement, Stand Up Therapeutics has the right to have VectorBuilder manufacture and commercialise future gene therapy products that it has designed. The objective is to dominate international trade.

According to VectorBuilder's head scientist, Bruce Lahn: "VectorBuilder is considering investing in Stand Up Therapeutics because of their interest in using their gene therapy to treat paralysis worldwide. I'm optimistic that VectorBuilder will be able to offer this product to Stand Up for Patients around the world given its position as a pioneer in the design and manufacture of GMP gene delivery vectors."

As stated by Stand Up Therapeutics' CEO and neurosurgeon, Dr. Junsang Yoo: "With its exclusive direct lineage reprogramming technique, Stand Up Therapeutics is the only firm in the world with the technology to heal paralysed patients with injured spinal cords" (STUP-001). Stand Up Therapeutics employees are devoting their lives to developing a cure for persons who have become paralysed as the result of a catastrophic event. As a bonus, "Stand Up Therapeutics plans to employ the direct cross-differentiation PIPELINE technology to produce medicines for Parkinson's disease (STUP-002), stroke (STUP-003), spinal stenosis (STUP-004), and myocardial infarction (STUP-005) in the future."

IIT Clinical will begin phase I/IIa research on STUP-001, a gene therapy treatment for spinal cord damage, with four paraplegic patients in the first quarter of 2023. (SCI).

In reference to Stand Up Therapeutics Co., Ltd.

The company Stand Up Therapeutics Co., Ltd. develops fibroblast-to-motor-neuron in vivo gene treatments for nerve cell regeneration. These treatments make use of state-of-the-art methods. Patients with both mild and severe paralysis will be able to benefit from Stand Up Therapeutics' direct lineage reprogramming method. Direct lineage reprogramming will be used to treat patients who have suffered spinal cord and brain damage and account for around 1.9% of the global population. By making direct reprogramming and gene therapy more reliable and secure, Stand Up Therapeutics will be able to add more medications to its pipeline.

Visit http://stutps.com for details.